@article{brugieres:hal-04228222,
TITLE = {Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS-crizotinib trial},
AUTHOR = {Brugi{\`e}res, Laurence and Cozic, Nathalie and Houot, Roch and Rigaud, Charlotte and Sibon, David and Arfi-Rouche, Julia and Bories, Pierre and Cottereau, Anne S and Delmer, Alain and Ducassou, St{\'e}phane and Garnier, Nathalie and Lamant, Laurence and Leruste, Amaury and Millot, Fr{\'e}d{\'e}ric and Moalla, S. and Morschhauser, Franck and Nolla, Marie and Pagnier, Anne and Reguerre, Yves and Renaud, Lo{\"i}c and Schmitt, Anne and Simonin, Mathieu and Verschuur, Arnaud and Labouret, Nathalie Hoog and Mahier Ait-Oukhatar, Celine and Vassal, Gilles},
URL = {https://hal.science/hal-04228222},
JOURNAL = {European Journal of Cancer},
PUBLISHER = {Elsevier},
VOLUME = {191},
PAGES = {112984},
YEAR = {2023},
DOI = {10.1016/j.ejca.2023.112984},
KEYWORDS = {Anaplastic large-cell lymphoma ALK plus ; Crizotinib ; ALK inhibitors},
PDF = {https://hal.science/hal-04228222/file/2023_Cozic_EurJCancer.pdf},
HAL_ID = {hal-04228222},
HAL_VERSION = {v1},
}